Clinical Trial
Published on 24 Oct 2019
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2019.01231
- 3,583 views